Using its high resolution expression profiling analysis, ExonHit said that it identifies novel transcripts coding for new protein variants that may be involved in various genetic disorders such as oncology, central nervous system (CNS), or immune system disorders. This mouse SpliceArray products represent the achievement of more two years of work by its R&D team after the launch of the human genome SpliceArray in 2007 and the rat genome SpliceArray earlier in 2008, the company added.
Loic Maurel, chairman of the executive board of ExonHit Therapeutics, said: “These new mouse SpliceArray products will further accelerate the understanding of mechanism of action and ultimately boost the discovery and validation of new therapeutics for ExonHit, using the mouse as a disease model system, especially in the fields of oncology and CNS disease, this unique approach enabling to save months of preclinical development time.”